Atezolizumab and other drugs before prostate surgery for high-risk cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed on biopsy, specifically adenocarcinoma (not small cell or neuroendocrine).
- Your cancer has not spread to other organs, and your surgeon says you are a candidate for prostate surgery.
- You have high-risk prostate cancer (intermediate-risk may be allowed later after safety checks).
- You have not had any prior medicines or radiation for prostate cancer, other than allowed “washout” from 5-alpha-reductase drugs.
- You can provide stored or new tumor tissue for study testing (tumor samples must be usable for lab analyses).
- Your overall health tests are adequate (blood counts, liver/kidney numbers, and heart/lung status), and you can follow study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.